1	Metabolite Signature of Life's Essential 8 and Risk of Coronary Heart Disease among
2	Low-Income Black and White Americans
3	
4	Kui Deng ¹ , Deepak K. Gupta ² , Xiao-Ou Shu ¹ , Loren Lipworth ¹ , Wei Zheng ¹ , Victoria E.
5	Thomas ² , Hui Cai ¹ , Qiuyin Cai ¹ , Thomas J. Wang ³ , Danxia Yu ¹
6	
7	¹ Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center,
8	Nashville, TN, USA
9	² Vanderbilt Translational and Clinical Cardiovascular Research Center and Division of
10	Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center,
11	Nashville, TN, USA
12	³ Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas,
13	Texas, USA
14	
15	Correspondence: Danxia Yu, Division of Epidemiology, Vanderbilt University Medical
16	Center, 2525 West End Avenue, Nashville, TN, USA 37203, Phone: (+1) 615-936-7389, Fax:
17	(+1) 615-343-5938, Email: <u>danxia.yu@vumc.org</u>

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

2

18 Abstract

19	Background and Aims: Life's Essential 8 (LE8) is a comprehensive construct of
20	cardiovascular health. Yet, little is known about LE8 score, its metabolic correlates, and their
21	predictive implications among Black Americans and low-income individuals.
22	Methods: In a nested case-control study of coronary heart disease (CHD) among 598 Black
23	and 596 White low-income Americans, we estimated LE8 score, conducted untargeted
24	plasma metabolites profiling, and used elastic net with leave-one-out cross-validation to
25	identify metabolite signature (MetaSig) of LE8. Associations of LE8 score and MetaSig with
26	incident CHD were examined using conditional logistic regression. Mediation effect of
27	MetaSig on the LE8-CHD association was also examined. The external validity of MetaSig
28	was evaluated in another nested CHD case-control study among 598 Chinese adults.
29	Results: Higher LE8 score was associated with lower CHD risk [standardized OR (95%
30	CI)=0.61 (0.53-0.69)]. The identified MetaSig, consisting of 133 metabolites, showed strong
31	correlation with LE8 score ($r=0.61$) and inverse association with CHD risk [OR (95%)
32	CI)=0.57 (0.49-0.65)], robust to adjustment for LE8 score and across participants with
33	different sociodemographic and health status (ORs: 0.42-0.69; all P<0.05). MetaSig mediated
34	a large portion of the LE8-CHD association: 53% (32%-80%) (P<0.001). Significant
35	associations of MetaSig with LE8 score and CHD risk were found in validation cohort
36	[<i>r</i> =0.49; OR (95% CI)=0.57 (0.46-0.69)].
37	Conclusions: Higher LE8 score and its MetaSig were associated with lower CHD risk among
38	low-income Black and White Americans. Metabolomics may offer an objective and
39	comprehensive measure of LE8 score and its metabolic phenotype relevant to CHD

- 40 prevention among diverse populations.
- 41
- 42 Keywords: Life's Essential 8; Cardiovascular Health; Coronary Heart Disease; Multi-racial
- 43 Population; Metabolomics

4

44 Introduction

45	Coronary heart disease (CHD) is a leading cause of morbidity and mortality in the United
46	States (US) and worldwide, with significant and persistent sociodemographic disparities ^{1,2} .
47	To reduce the burden and life lost due to CHD and other cardiovascular disease (CVD), the
48	American Heart Association (AHA) has recently proposed Life's Essential 8 (LE8) to assess
49	and promote cardiovascular health (CVH) in individuals and populations ³ . LE8 includes 4
50	health behaviors (healthy diet, participation in physical activity, avoidance of nicotine, and
51	healthy sleep [a new component of LE8]) and 4 health factors (weight, blood lipids, glucose,
52	and blood pressure), and has a new scoring system with continuous scale to better reflect
53	inter-individual differences. While a higher LE8 score has been recently associated with
54	lower CVD incidence and mortality ⁴⁻⁷ , few studies have evaluated LE8 score and its
55	association with incident CVD among Black and White Americans who have low
56	socioeconomic status (SES) and face disproportionate CVD burdens. In addition, although
57	some potential mechanisms have been identified (e.g., reduced inflammation and
58	atherosclerosis) ^{8,9} , beyond those known CVD risk pathways, mechanisms and inter-
59	individual differences underlying the cardioprotective effects of LE8 and its included health
60	behaviors and health factors are not fully understood.

61

Metabolite profiling ("metabolomics") comprehensively measures small-molecule metabolites (including substrates, intermediates, and end products) in biological samples and represents a powerful tool for mechanistic investigation, novel biomarker discovery, and precision medicine^{10,11}. Metabolite profiling of blood samples may improve assessments of

66	individuals' alignment with LE8, particularly for behavioral factors that are prone to survey
67	and recall biases. In addition, circulating metabolites related to LE8 may capture varied
68	individual metabolic responses to LE8, providing novel mechanistic insights into its
69	cardioprotective effects and informing precision medicine. While previous studies have
70	identified metabolites related to the components of LE8, including diet ¹²⁻¹⁶ , physical
71	activity ¹⁷⁻¹⁹ , tobacco exposure ²⁰⁻²² , sleep ²³⁻²⁶ , and body mass index (BMI) ^{27,28} , to our
72	knowledge, no study has applied untargeted plasma metabolomics to identify a
73	comprehensive metabolite signature (MetaSig) for LE8 to enable studies with incident CHD.
74	Given that those health behaviors and factors often correlate and interact with each other,
75	investigating whether plasma metabolomics could provide a good objective assessment of
76	individuals' alignment with and metabolic responses to overall LE8 and uncovering potential
77	pathways linking LE8 to incident CHD is highly warranted.
78	
79	Here, leveraging a case-control study of CHD nested within the Southern Community
80	Cohort Study (SCCS) involving 598 Black Americans and 596 White Americans, we
81	assessed the LE8 score and its MetaSig and examined their relations to incident CHD. The
82	results were further replicated in another nested CHD case-control study of racially and
83	geographically different population: 598 Chinese adults from the Shanghai Women's Health
84	Study and Shanghai Men's Health Studies (SWMHS). In addition, we identified MetaSigs for
85	the health behaviors and health factors recommended in the LE8 and evaluated their
86	associations with incident CHD.
87	

6

88 Methods

89 Study participants

This study was based on a nested case-control study of CHD within the SCCS²⁹. Briefly, 90 the SCCS enrolled 84,735 primarily low-income, uninsured/underinsured Black and White 91 92 Americans aged 40-79 years from 12 southeastern US states between 2002-2009, with >50% having household income less than \$15,000/y and \sim 86% were uninsured or underinsured²⁹. 93 Participants were surveyed for a wide range of information at baseline and followed up 94 regularly for morbidity and mortality outcomes. Venous blood samples were collected at 95 96 baseline, and plasma samples were aliquoted and stored at -80°C for long-term use. A nested case-control study of CHD within SWMHS was used as the validation cohort, which enrolled 97 74,940 women, aged 40-70 years, and 61,480 men, aged 40-74 years, from Shanghai, China 98 between 1996–2000 and 2002–2006, respectively^{30,31}. These cohort studies were approved by 99 the Institutional Review Boards of the Vanderbilt University Medical Center, Meharry 100 Medical College, and/or Shanghai Cancer Institute. Informed consent was obtained from all 101 102 enrolled participants.

103

For the nested case-control studies, participant inclusion criteria were 1) no history of CHD, stroke, heart failure, cancer, or end-stage renal disease at baseline; 2) available baseline plasma samples and data on fasting time and in SCCS, time between sample collection and lab processing; 3) no use of antibiotics nor cold/flu in last 7 days before blood collection. In addition, to facilitate CHD case identification and adjudication, in SCCS, participants were eligible for Centers for Medicare & Medicaid Services (CMS) and had ≥ 2 claims after cohort

7

110	enrollment; in SWMHS, participants' medical records were accessible for our study. In
111	SCCS, nonfatal CHD cases were identified through CMS, including acute myocardial
112	infarction, coronary revascularization, and other acute CHD, and CHD deaths were identified
113	through the National Death Index. In SWMHS, CHD cases were first identified by self-
114	reported diagnoses during follow-up visits and then confirmed by medical records. In each
115	race (Black, White, or Chinese) and gender (male or female), 150 incident CHD cases were
116	randomly selected and 1:1 matched with controls who had no CHD, heart failure, stroke, nor
117	cancer at the time of case diagnosis, by enrollment age (± 2 years), fasting time (± 2 hours),
118	and time between sample collection and lab processing (±4 hours, for SCCS samples; all
119	SWMHS samples were processed within 6 hours after collection). After excluding eight
120	plasma samples that did not pass the metabolite profiling quality control, a total of 1792
121	participants, including 597 pairs of CHD cases and controls in SCCS (299 pairs of Black
122	Americans and 298 pairs of White Americans), and 299 pairs of Chinese adults in SWMHS
123	were included in the present study (Fig. 1).
124	

125 Life's Essential 8

We constructed each LE8 component metric and total LE8 score (ranging from 0 to 100) according to AHA guidelines^{3,32}, with some modifications based on the characteristics of our data, as shown in **Table S1**. Briefly, dietary quality was assessed by the Dietary Approaches to Stop Hypertension (DASH) score³³⁻³⁵. Physical activity was measured by total minutes of leisure-time moderate and vigorous physical activity per week, with each minute of vigorous physical activity counted as 2 minutes toward the total minutes. Nicotine exposure was

8

132	assessed by active tobacco smoking and secondhand smoking exposure. Sleep health was
133	measured by average self-reported sleep hours per day. BMI was calculated as weight
134	(kg)/height (m) ² . Blood lipids component was assessed by non-HDL cholesterol (mg/dL)
135	(plasma total cholesterol minus HDL cholesterol). Because concentrations of fasting glucose
136	and HbA1c were not measured in our study, blood glucose component was scored based on
137	diabetes diagnosis and medications and relative abundance of plasma glucose measured
138	simultaneously with other metabolites (see following metabolite profiling methods). Blood
139	pressure was unavailable in SCCS, thus blood pressure component was scored based on
140	hypertension status and medications. Total LE8 score was obtained by calculating the
141	arithmetic mean of individual component scores. We also calculated scores reflecting
142	alignment with health behaviors and health factors.

143

144 Metabolite profiling

Baseline plasma samples of selected CHD case-control pairs were retrieved and placed 145 146 adjacently in the same assay batch. Laboratory persons were blinded to the case-control status of samples. Untargeted metabolite profiling was performed using ultra-high-performance 147 liquid chromatography (UHPLC) coupled with tandem mass spectrometry (MS) by 148 Metabolon Inc. (Morrisville, NC, USA) following a standard assay protocol³⁶. Briefly, 149 plasma samples were extracted with methanol and split into four aliquots for analysis by 150 UHPLC-MS/MS in both positive and negative ion modes using a combination reverse phase 151 and HILIC chromatography methods. Metabolites were identified by automated comparison 152 of mass spectra features to a reference library of >4,000 authenticated standard compounds 153

154	followed by visual inspection for quality control. Peaks were quantified using area-under-the-
155	curve. A total of 1502 metabolites were detected in our samples. The majority of metabolites
156	(>80%) were annotated based on internal standards. Metabolites that were annotated only by
157	a match to a known MS spectrum or chemical formula were marked by '*' and '**',
158	respectively. We excluded metabolites detected in <10% of participants, resulting in 1322
159	metabolites. Metabolites with missing values were imputed by half of the minimal value in
160	the non-missing samples. The values of all metabolites were log-transformed and
161	standardized to mean 0 and unit variance.
162	
163	Statistical analysis
164	The characteristics of the study participants were presented as mean (standard deviation
165	[SD]) for continuous variables and frequency (percentage) for categorical variables.
166	Spearman correlations between LE8 score and individual component scores were assessed.
167	Elastic net regression was used to identify metabolites associated with LE8 ^{12,14,37} , with
168	hyperparameters determined via a ten-repeated tenfold cross-validation framework, using R
169	package caret (version: 6.0-88) ³⁸ and glmnet (version: 4.1-3) ^{37,39} . The MetaSig was calculated
170	through a leave-one-out cross-validation approach. In addition, we externally validated the
171	identified signature in SWMHS using weights of the selected metabolites from SCCS. We
172	calculated Spearman correlations between LE8 score and MetaSig among all participants and
173	by race, sex, age (≥60y/<60y), incident CHD status, diabetes status, hypertension status,
174	dyslipidemia status, and fasting status.

176	We then examined the associations of LE8 and its MetaSig with risk of CHD using
177	conditional logistic regression, adjusting for age, education, income, alcohol intake, and
178	family history of CHD. We also included LE8 score and MetaSig in the same model to assess
179	their independent associations with CHD and potential mediating effect of MetaSig on LE8-
180	CHD association. The potential multicollinearity was assessed by variance inflation factor
181	(VIF) using R package car (version: 3.1-0) with VIF >10 indicating multicollinearity among
182	variables. The ranges of VIF for LE8 score and its MetaSig were 1.08-1.37, confirming no
183	multicollinearity. The mediation analysis was performed using R package mediation (version:
184	4.5.0) ⁴⁰ . Subgroup analyses to evaluate the associations of LE8 and MetaSig with incident
185	CHD were performed by race, age group, sex, education, household income, diabetes status,
186	hypertension status, and dyslipidemia status, with P value for interaction obtained from the
187	corresponding interaction term in the model.
188	
189	The same methods were used to identify MetaSigs for health behaviors and health factors
190	included in LE8 and evaluate their associations with incident CHD, potential mediation
191	effects, and their external validity. Mutual adjustments of health behaviors and health factors
192	score were performed in corresponding statistical models. All analyses were performed using
193	R (version 4.1.1). Two-sided $P < 0.05$ was considered statistically significant. An overview of
194	our study design is presented in Fig. 1.

11

196 **Results**

197 Baseline characteristics of study participants

The mean age at baseline (blood collection) was 55 years in our study participants (Table 198 1). The mean (SD) of LE8 score was 48.1 (12.3) in Black women, 50.0 (13.6) in Black men, 199 48.1 (13.4) in White women, and 48.5 (14.4) in White men. The median follow-up time for 200 incident CHD cases was 5 (interquartile range: 3-8) years in SCCS. Incident CHD cases had 201 significantly lower total LE8 score, health behaviors score, and health factors score than 202 controls (all P < 0.05). The characteristics of participants in SWMHS (mean age: 61 years; 203 204 mean LE8 score: 57.2 in women and 50.7 in men) are shown in Table S2. There were moderate correlations between total LE8 score and individual component scores (r ranged 205 from 0.22 with smoking to 0.47 with BMI and blood pressure scores in SCCS; Fig. S1). 206 207

208 Metabolite signature of LE8

We identified 133 metabolites related to LE8 (top 30 are shown in Fig. 2A; the full list 209 210 can be found in Table S3). The MetaSig was strongly correlated with LE8 score (r = 0.61, P<0.001; Fig. 2B), meanwhile variations in MetaSig were observed among individuals with 211 the same LE8 score, demonstrating interindividual difference in metabolic phenotype of LE8. 212 MetaSig was also correlated with LE8 score in SWMHS (r = 0.49, P < 0.001; Fig. 2C). 213 Stratified analyses showed that correlations between LE8 score and MetaSig were consistent 214 regardless of age, sex, race, fasting status, diabetes status, hypertension status, dyslipidemia 215 status, and incident CHD status (r ranged from 0.54 to 0.64; Table S4), suggesting the 216 robustness of our identified LE8 metabolite signature across participants with different 217

12

218 sociodemographic backgrounds and metabolic disease status.

219

220 Associations with incident CHD

- Higher LE8 score and its MetaSig were significantly associated with lower risk of CHD:
- standardized multivariable-adjusted odds ratio (OR) = 0.61 (95% CI: 0.53-0.69) for LE8
- score and 0.57 (0.49-0.65) for MetaSig; both P < 0.001 (**Table 2**). Sensitivity analysis
- showed that the MetaSig-CHD associations did not change after excluding any individual
- 225 metabolites from the signature (Table S5). After further adjusting for LE8 score, the
- MetaSig-CHD association was only slightly attenuated [OR (95% CI) = 0.66 (0.55-0.78);

227 P<0.001; Table 2], suggesting circulating metabolites may complement LE8 assessment and

228 contribute to CHD risk beyond LE8 score. On the other hand, the LE8-CHD association was

moderately attenuated after adjusting for MetaSig [OR (95% CI) = 0.78 (0.66-0.92),

230 *P*=0.003]. Mediation analysis showed that MetaSig mediated a large portion of the LE8-CHD

association [53% (32%-80%); *P*_{mediation}<0.001; **Fig. 2D**].

Both LE8 and its MetaSig were inversely associated with CHD risk in subpopulations by

race, age group, education, income, diabetes status, hypertension status, and dyslipidemia

status ($P_{\text{interaction}} > 0.05$; Fig. 3), with stronger associations observed in women than in men [for

235 LE8, OR (95% CI) = 0.53 (0.42-0.66) in women and 0.66 (0.55-0.80) in men, $P_{\text{interaction}} =$

- 236 0.017; for MetaSig, 0.48 (0.38-0.6) in women and 0.65 (0.54-0.78) in men, $P_{\text{interaction}} = 0.016$].
- 237 The association of MetaSig with incident CHD was replicated in SWMHS (Table 2),
- with OR (95% CI) = 0.57 (0.46-0.69) and 0.69 (0.55-0.86) after further adjusting for LE8
- score (both $P \le 0.001$). The MetaSig also mediated a considerable portion of the LE8-CHD

13

240 association in SWMHS [27.4% (10%-47%); *P*_{mediation}<0.001; Fig. 2E].

241

242	Metabolite signatures of health behaviors and health factors and associations with CHD
243	We further identified MetaSigs for health behaviors (Fig. S2A) and health factors in
244	SCCS (Fig. S3A; full lists of metabolites are shown in Table S3), which showed strong
245	correlations with health behaviors score ($r = 0.59$, $P < 0.001$; Fig. S2B) and with health factors
246	score ($r = 0.76$, $P < 0.001$; Fig. S3B). Significant correlations were also found among
247	participant subgroups (Table S4), suggesting the robustness of identified metabolite
248	signatures for health behaviors and health factors. In addition, there were significant inverse
249	associations of health behaviors score, health factors score, and their related signatures with
250	risk of CHD (all P<0.001; Table 2). Specifically, standardized OR (95% CI) was 0.73 (0.63-
251	0.85) for health behaviors MetaSig and 0.57 (0.49-0.66) for health factors MetaSig. Similarly,
252	metabolites mediated large portions of the health behaviors-CHD association [43.9% (13.9%-
253	101%), P=0.004; Fig. S2D] and health factors-CHD association [53.2% (24.8%-89%),
254	$P_{\text{mediation}} < 0.001$; Fig. S3D]. Further, all results on health behaviors MetaSig and health factors
255	MetaSig were replicated in SWMHS (Table 2, Fig. S2, and Fig. S3).
256	

257 **Discussion**

Leveraging untargeted plasma metabolites data in a nested case-control study among low-income Black and White Americans, we identified a metabolite signature that could reflect LE8 score and was associated with incident CHD, even after adjusting for LE8 and among participants with varied sociodemographic and metabolic health status, suggesting

14

262	that circulating metabolite profiling may be used to help assess LE8 alignment across diverse
263	populations and offer additional information on CVH (e.g., inter-individual metabolic
264	phenotypes related to LE8). We also identified MetaSigs for health behaviors and health
265	factors and found consistent results showing that circulating metabolites could reflect the
266	alignment with those recommendations and underlying metabolic phenotypes, which were
267	further linked to incident CHD across diverse populations. All the results were further
268	replicated in another nested case-control study of CHD among Chinese adults. Our findings
269	demonstrate the potential utility of blood metabolomics to improve the assessment of LE8
270	and its underlying metabolic variations that are linked to incident CHD among
271	sociodemographically diverse populations, towards advancing precision medicine and
272	addressing disparities in CVH.
273	

LE8 is the American Heart Association's updated and enhanced guideline to measure and 274 promote CVH for individuals and populations³. The beneficial associations of following the 275 276 LE8 with lower risks of CHD, CVD, and related mortality have been demonstrated in recent studies⁴⁻⁷. However, multi-racial/ethnic populations with low SES remain underrepresented in 277 research studies, even though they have persistently experienced worse CVH and CVD 278 outcomes, as well as systemic disadvantages to improve CVH, than White and middle-class 279 Americans^{2,41-43}. Leveraging resources from SCCS, a large cohort of predominantly low-280 income Black and White Americans (in the present study: ~65% with household income 281 <\$15,000/y and ~95% with household income <\$25,000/y), our study assessed CVH based 282 on LE8 and evaluated the association of LE8 score with incident CHD. We found that higher 283

284	LE8 score (per SD increase) was associated with \sim 40-50% lower risk of CHD among Black
285	Americans and individuals with low SES. While LE8 provides a comprehensive approach to
286	quantify CVH, its assessment involves a series of procedures such as questionnaires,
287	anthropometric and blood pressure measures, and blood draw. Particularly, health behaviors
288	(diet, physical activity, smoking, and sleep) are usually assessed by questionnaires, which are
289	time-consuming and prone to measurement errors and low compliance (particularly in the
290	clinical setting). Also, LE8 score cannot capture varied individual metabolic responses to
291	lifestyle exposures. Hence, we incorporated untargeted plasma metabolomics data, and for
292	the first time, identified a robust metabolite signature of LE8 and then examined its
293	association with incident CHD.
294	
295	Metabolomics has been demonstrated as a powerful tool for improving exposure
296	assessment and identifying potential novel biomarkers and mechanistic pathways in
297	population studies, given its high-throughput characterization of thousands of metabolites in a
298	small amount of biological samples ⁴⁴ . Our study provides new evidence that plasma
299	metabolite profiling may provide objective and comprehensive measures of LE8 and CVH
300	among racially and geographically diverse populations. The identified metabolite signature
301	may complement LE8 scores, improve the precision to stratify individuals with different
302	future CHD risk, and potentially facilitate personalized CHD prevention strategies.
303	
304	
004	Our identified MetaSig consists of metabolites reflecting participants' alignment with

306	acids, and many of them have been linked to diet ¹²⁻¹⁶ , physical activity ¹⁷⁻¹⁹ , smoking ²⁰⁻²² ,
307	sleep ²³⁻²⁶ , obesity ^{27,28,45} , or composite lifestyles scores ⁴⁶⁻⁴⁹ in previous studies. For example,
308	(2,4 or 2,5)-dimethylphenol sulfate, tartronate, and ethyl beta-glucopyranoside are derived
309	from plant-based foods; cotinine is the major metabolite of nicotine from tobacco smoking;
310	cholesterol, sphingomyelin, cortisol, and 1-palmitoleoylglycerolare are related to blood
311	lipids; mannose, metformin, and fructosyllysine are related to prevalent diabetes and blood
312	glucose. Particularly, drug metabolites including hydrochlorothiazide and metformin reflect
313	antihypertensive and antidiabetic medications defined in LE8. Nevertheless, the associations
314	of MetaSig with LE8 score and incident CHD were consistent among participants with or
315	without history of hypertension or diabetes (Fig. 3 and Table S4), and the MetaSig-CHD
316	association did not change after excluding those drug metabolites from the MetaSig [OR
317	(95% CI)=0.55 (0.48-0.64); P<0.001]. Moreover, excluding 29 unknown metabolites (X-)
318	from the MetaSig also did not change the MetaSig-CHD association [OR (95% CI)=0.58
319	(0.50-0.66); $P < 0.001$]. Notably, the MetaSig also contains microbial metabolites, e.g.,
320	maltotetraose, anthranilate, indolebutyrate, and bile acids (taurohyocholate,
321	glycodeoxycholate 3-sulfate, 3b-hydroxy-5-cholenoic acid, and glycohyocholate), suggesting
322	the role of gut microbiome in host's CVH, which cannot be captured by questionnaires or
323	measurements of glucose, cholesterol, or blood pressure. Moreover, several metabolic
324	pathways related to CVH and CVD development were highlighted. For example, anthranilate,
325	indolebutyrate, picolinate, and serotonin are members of tryptophan metabolism pathway ⁵⁰⁻⁵² ;
326	taurohyocholate, glycodeoxycholate 3-sulfate, 3b-hydroxy-5-cholenoic acid, and
327	glycohyocholate belong to secondary bile acid metabolism pathway ^{53,54} ; alpha-tocopherol,

17

delta-tocopherol, and gamma-tocopherol/beta-tocopherol are vitamin E derivatives through
 tocopherol metabolism pathway^{55,56}.

330

331	Importantly, the MetaSig was related to future CHD risk regardless of participants' age,
332	sex, race, SES, metabolic disease history, and even after adjustment for LE8. Further analyses
333	indicated that circulating metabolites could play a substantial mediating role linking LE8 and
334	reduced CHD risk. Moreover, our findings were replicated in a racially and geographically
335	different population, suggesting external validity and potential generalizability of our
336	findings. Taken together, our findings demonstrated that circulating metabolites could
337	complement LE8 to improve the precision of CVH assessment and predict CHD risk among
338	sociodemographically and geographically diverse populations.
339	

To our knowledge, this is the first study that assessed the LE8 score, constructed its 340 metabolite signature, and associated LE8 score and its MetaSig with incident CHD in Black 341 342 and White Americans with low SES. Besides its novelty and inclusion of populations facing socioeconomic challenges and health disparities, other strengths of our study include its 343 prospective design, comprehensive profiling of >1500 blood metabolites for a broad coverage 344 and improved ability to construct metabolite signature for LE8, and robustness of results 345 across populations with different sociodemographic and health status. Meanwhile, several 346 limitations of our current study need to be acknowledged. First, as MetaSig of LE8 was 347 identified using cross-sectional data from baseline blood samples, we cannot be certain as to 348 the directionality of LE8-MetaSig association, and mediation analysis assumed that LE8 349

18

350	score preceded MetaSig. Although several population- or animal-based studies have shown
351	the causal effects of LE8 components on blood metabolites ^{21,26,57-60} , given that blood
352	metabolites might precede some LE8 components, the longitudinal association between LE8
353	adherence and circulating metabolites should be investigated. Second, given the observational
354	nature of our study, the causality is unable to be confirmed. However, the prospective design
355	reduces the concern of reverse causation for the LE8/MetaSig-CHD association. Third, we
356	cannot rule out the influence of residual confounding on the LE8/MetaSig-CHD association,
357	although we have adjusted for and stratified by major CHD risk factors. Fourth, the
358	concentrations of fasting glucose and HbA1c and SBP and DBP were not measured in SSCS;
359	thus, glucose score and blood pressure score were defined based on history of diabetes or
360	hypertension and use of medications, which may influence the accuracy of LE8 score.
361	Finally, the nested case-control design may overestimate the predictive ability of the LE8
362	score and its MetaSig. Therefore, our results should be further validated in other prospective
363	cohort studies.
364	
365	In summary, our study assessed the LE8 score and identified MetaSig of LE8 among
366	low-income Black and White Americans. We found that both LE8 score and its MetaSig were

367 inversely associated with risk of CHD, consistently among participants with varied

368 sociodemographic and metabolic health status. Our identified metabolite signature may

369 provide an objective and comprehensive measure of LE8 and its metabolic underpinning,

370 which may help improve the precision of CVH assessment and facilitate more effective and

371 personalized CHD prevention strategies in diverse populations. Further examination of our

- 372 identified metabolites may improve understanding of biological mechanisms as how
- 373 following LE8 benefits CHD prevention.

20

374 Acknowledgments

The authors thank the study participants of the SCCS and the SWMHS.

376

377 Funding

- 378 The Southern Community Cohort Study is funded by U01 CA202979, the Shanghai Women's
- Health Study is funded by UM1 CA182910, and the Shanghai Men's Health Study is funded
- by UM1 CA173640 from the National Cancer Institute (NCI) at the National Institutes of
- 381 Health (NIH). Biospecimens of these three cohort studies are managed by the Survey and
- 382 Biospecimen Shared Resource, which is supported in part by the Vanderbilt-Ingram Cancer
- 383 Center (P30 CA68485). This study is supported by R01 HL149779 from the National Heart,
- Lung, and Blood Institute (NHLBI) at the NIH. The content is solely the responsibility of the
- authors and does not necessarily represent the official views of the National Institutes of
- 386 Health.

387

388 Conflict of interest

389 The authors declared no conflict of interest.

21

390 **References**

- 1. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a
- 392 systematic analysis for the Global Burden of Disease Study 2019. *Lancet* 2020;**396**:1204-1222.
- 393 doi: 10.1016/s0140-6736(20)30925-9
- 2. Tsao CW, Aday AW, Almarzooq ZI, *et al.* Heart Disease and Stroke Statistics-2023 Update:
- 395 A Report From the American Heart Association. *Circulation* 2023. doi:
 396 10.1161/cir.00000000001123
- 397 3. Lloyd-Jones DM, Allen NB, Anderson CA, et al. Life's essential 8: updating and
- 398 enhancing the American Heart Association's Construct of Cardiovascular Health: a presidential
- advisory from the American Heart Association. *Circulation* 2022;**146**:e18-e43. doi:
- 400 4. Wang X, Ma H, Li X, et al. Association of Cardiovascular Health With Life Expectancy
- 401 Free of Cardiovascular Disease, Diabetes, Cancer, and Dementia in UK Adults. JAMA Intern
- 402 *Med* 2023. doi: 10.1001/jamainternmed.2023.0015
- 403 5. Isiozor NM, Kunutsor SK, Voutilainen A, Laukkanen JA. Life's Essential 8 and the risk of
- 404 cardiovascular disease death and all-cause mortality in Finnish men. Eur J Prev Cardiol 2023.
- 405 doi: 10.1093/eurjpc/zwad040
- 406 6. Jin C, Li J, Liu F, et al. Life's Essential 8 and 10-Year and Lifetime Risk of Atherosclerotic
- 407 Cardiovascular Disease in China. Am J Prev Med 2023. doi: 10.1016/j.amepre.2023.01.009
- 408 7. Yi J, Wang L, Guo X, Ren X. Association of Life's Essential 8 with all-cause and
- 409 cardiovascular mortality among US adults: A prospective cohort study from the NHANES
- 410 2005-2014. Nutr Metab Cardiovasc Dis 2023. doi: 10.1016/j.numecd.2023.01.021
- 411 8. Xanthakis V, Enserro DM, Murabito JM, et al. Ideal cardiovascular health: associations

with biomarkers and subclinical disease and impact on incidence of cardiovascular disease in

the Framingham Offspring Study. *Circulation* 2014;**130**:1676-1683. doi:

414	9. Gaye B, Tafflet M, Arveiler D, et al. Ideal cardiovascular health and incident
415	cardiovascular disease: heterogeneity across event subtypes and mediating effect of blood
416	biomarkers: the prime study. Journal of the American Heart Association 2017;6:e006389. doi:
417	10. Després JP. Predicting longevity using metabolomics: a novel tool for precision lifestyle
418	medicine? Nat Rev Cardiol 2020;17:67-68. doi: 10.1038/s41569-019-0310-2
419	11. Clish CB. Metabolomics: an emerging but powerful tool for precision medicine. Molecular
420	Case Studies 2015;1:a000588. doi:
421	12. Li J, Guasch-Ferré M, Chung W, et al. The Mediterranean diet, plasma metabolome, and
422	cardiovascular disease risk. Eur Heart J 2020;41:2645-2656. doi: 10.1093/eurheartj/ehaa209
423	13. Chen L, Zhernakova DV, Kurilshikov A, et al. Influence of the microbiome, diet and
424	genetics on inter-individual variation in the human plasma metabolome. Nat Med 2022. doi:
425	10.1038/s41591-022-02014-8
426	14. Wang F, Baden MY, Guasch-Ferré M, et al. Plasma metabolite profiles related to plant-
427	based diets and the risk of type 2 diabetes. Diabetologia 2022;65:1119-1132. doi:
428	10.1007/s00125-022-05692-8
429	15. Chen GC, Chai JC, Xing J, et al. Healthful eating patterns, serum metabolite profile and
430	risk of diabetes in a population-based prospective study of US Hispanics/Latinos. Diabetologia
431	2022; 65 :1133-1144. doi: 10.1007/s00125-022-05690-w
432	16. Shah RV, Steffen LM, Nayor M, et al. Dietary metabolic signatures and cardiometabolic
433	risk. European Heart Journal 2022. doi:

- 434 17. Kemppainen SM, Fernandes Silva L, Lankinen MA, Schwab U, Laakso M. Metabolite
- 435 Signature of Physical Activity and the Risk of Type 2 Diabetes in 7271 Men. *Metabolites*
- 436 2022;**12**. doi: 10.3390/metabo12010069
- 437 18. Kujala UM, Mäkinen VP, Heinonen I, et al. Long-term leisure-time physical activity and
- 438 serum metabolome. *Circulation* 2013;**127**:340-348. doi: 10.1161/circulationaha.112.105551
- 439 19. Ding M, Zeleznik OA, Guasch-Ferre M, *et al.* Metabolome-Wide Association Study of the
- 440 Relationship Between Habitual Physical Activity and Plasma Metabolite Levels. Am J
- 441 *Epidemiol* 2019;**188**:1932-1943. doi: 10.1093/aje/kwz171
- 442 20. Tan Y, Barr DB, Ryan PB, et al. High-resolution metabolomics of exposure to tobacco
- smoke during pregnancy and adverse birth outcomes in the Atlanta African American maternal-
- 444 child cohort. *Environ Pollut* 2022;**292**:118361. doi: 10.1016/j.envpol.2021.118361
- 445 21. Xu T, Holzapfel C, Dong X, et al. Effects of smoking and smoking cessation on human
- serum metabolite profile: results from the KORA cohort study. *BMC Med* 2013;11:60. doi:
- 447 10.1186/1741-7015-11-60
- 448 22. Gu F, Derkach A, Freedman ND, *et al.* Cigarette smoking behaviour and blood
 449 metabolomics. *Int J Epidemiol* 2016;45:1421-1432. doi: 10.1093/ije/dyv330
- 23. Bos MM, Goulding NJ, Lee MA, *et al.* Investigating the relationships between
 unfavourable habitual sleep and metabolomic traits: evidence from multi-cohort multivariable
 regression and Mendelian randomization analyses. *BMC Med* 2021;19:69. doi:
 10.1186/s12916-021-01939-0
- 454 24. Fritz J, Huang T, Depner CM, *et al.* Sleep duration, plasma metabolites, and obesity and
- 455 diabetes: A metabolome-wide association study in US women. Sleep 2022. doi:

- 456 10.1093/sleep/zsac226
- 457 25. Topriceanu CC, Tillin T, Chaturvedi N, Joshi R, Garfield V. The association between
- 458 plasma metabolites and sleep quality in the Southall and Brent Revisited (SABRE) Study: A
- 459 cross-sectional analysis. J Sleep Res 2021;**30**:e13245. doi: 10.1111/jsr.13245
- 460 26. Huang T, Zeleznik OA, Poole EM, et al. Habitual sleep quality, plasma metabolites and
- risk of coronary heart disease in post-menopausal women. *Int J Epidemiol* 2019;**48**:1262-1274.
- 462 doi: 10.1093/ije/dyy234
- 463 27. Pan XF, Chen ZZ, Wang TJ, et al. Plasma metabolomic signatures of obesity and risk of
- 464 type 2 diabetes. Obesity (Silver Spring) 2022. doi: 10.1002/oby.23549
- 465 28. Ottosson F, Smith E, Ericson U, *et al.* Metabolome-Defined Obesity and the Risk of Future
- 466 Type 2 Diabetes and Mortality. *Diabetes Care* 2022;**45**:1260-1267. doi: 10.2337/dc21-2402
- 467 29. Signorello LB, Hargreaves MK, Blot WJ. The Southern Community Cohort Study:
- investigating health disparities. J Health Care Poor Underserved 2010;21:26-37. doi:
 10.1353/hpu.0.0245
- 470 30. Zheng W, Chow WH, Yang G, *et al.* The Shanghai Women's Health Study: rationale, study
- 471 design, and baseline characteristics. *Am J Epidemiol* 2005;162:1123-1131. doi:
 472 10.1093/aje/kwi322
- 473 31. Shu XO, Li H, Yang G, *et al.* Cohort Profile: The Shanghai Men's Health Study. *Int J*474 *Epidemiol* 2015;44:810-818. doi: 10.1093/ije/dyv013
- 475 32. Lloyd-Jones DM, Ning H, Labarthe D, *et al.* Status of Cardiovascular Health in US Adults
- 476 and Children Using the American Heart Association's New "Life's Essential 8" Metrics:
- 477 Prevalence Estimates From the National Health and Nutrition Examination Survey (NHANES),

- 478 2013 Through 2018. Circulation 2022;146:822-835. doi: 10.1161/circulationaha.122.060911
- 479 33. Mellen PB, Gao SK, Vitolins MZ, Goff DC. Deteriorating dietary habits among adults with
- 480 hypertension: DASH dietary accordance, NHANES 1988-1994 and 1999-2004. Archives of

481 *internal medicine* 2008;**168**:308-314. doi:

- 482 34. Chang RS, Xu M, Brown SH, *et al.* Relation of the Dietary Approaches to Stop
 483 Hypertension Dietary Pattern to Heart Failure Risk and Socioeconomic Status (from the
- 484 Southern Community Cohort Study). Am J Cardiol 2022;169:71-77. doi:
- 485 10.1016/j.amjcard.2021.12.043
- 486 35. Yu D, Zhang X, Xiang YB, et al. Adherence to dietary guidelines and mortality: a report
- from prospective cohort studies of 134,000 Chinese adults in urban Shanghai. *Am J Clin Nutr*2014;100:693-700. doi: 10.3945/ajcn.113.079194
- 489 36. Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E. Integrated, nontargeted
- 490 ultrahigh performance liquid chromatography/electrospray ionization tandem mass
- 491 spectrometry platform for the identification and relative quantification of the small-molecule
- 492 complement of biological systems. *Anal Chem* 2009;**81**:6656-6667. doi: 10.1021/ac901536h
- 37. Zou H, Hastie T. Regularization and variable selection via the elastic net. *Journal of the royal statistical society: series B (statistical methodology)* 2005;67:301-320. doi:
- 38. Kuhn M. Building predictive models in R using the caret package. *Journal of statistical software* 2008;**28**:1-26. doi:
- 497 39. Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via
 498 coordinate descent. *Journal of statistical software* 2010;**33**:1. doi:
- 499 40. Tingley D, Yamamoto T, Hirose K, Keele L, Imai K. Mediation: R package for causal

- 500 mediation analysis. 2014. doi:
- 41. Huffman MD, Capewell S, Ning H, et al. Cardiovascular health behavior and health factor
- 502 changes (1988-2008) and projections to 2020: results from the National Health and Nutrition
- 503 Examination Surveys. *Circulation* 2012;**125**:2595-2602. doi:
- 504 10.1161/circulationaha.111.070722
- 42. Pilkerton CS, Singh SS, Bias TK, Frisbee SJ. Changes in Cardiovascular Health in the
- 506 United States, 2003-2011. J Am Heart Assoc 2015;4:e001650. doi: 10.1161/jaha.114.001650
- 43. Haynes N, Kaur A, Swain J, Joseph JJ, Brewer LC. Community-Based Participatory
- 508 Research to Improve Cardiovascular Health Among US Racial and Ethnic Minority Groups.
- 509 *Curr Epidemiol Rep* 2022;**9**:212-221. doi: 10.1007/s40471-022-00298-5
- 44. Wishart DS. Emerging applications of metabolomics in drug discovery and precision
 medicine. *Nature reviews Drug discovery* 2016;15:473-484. doi:
- 45. Cirulli ET, Guo L, Leon Swisher C, et al. Profound Perturbation of the Metabolome in
- 513 Obesity Is Associated with Health Risk. *Cell Metab* 2019;**29**:488-500.e482. doi: 514 10.1016/j.cmet.2018.09.022
- 515 46. Delgado-Velandia M, Gonzalez-Marrachelli V, Domingo-Relloso A, et al. Healthy
- 516 lifestyle, metabolomics and incident type 2 diabetes in a population-based cohort from Spain.
- 517 Int J Behav Nutr Phys Act 2022;19:8. doi: 10.1186/s12966-021-01219-3
- 518 47. Rothwell JA, Murphy N, Bešević J, et al. Metabolic Signatures of Healthy Lifestyle
- 519 Patterns and Colorectal Cancer Risk in a European Cohort. Clin Gastroenterol Hepatol
- 520 2022;**20**:e1061-e1082. doi: 10.1016/j.cgh.2020.11.045
- 48. Assi N, Gunter MJ, Thomas DC, et al. Metabolic signature of healthy lifestyle and its

- 522 relation with risk of hepatocellular carcinoma in a large European cohort. Am J Clin Nutr
- 523 2018;108:117-126. doi: 10.1093/ajcn/nqy074
- 49. Si J, Li J, Yu C, et al. Improved lipidomic profile mediates the effects of adherence to
- healthy lifestyles on coronary heart disease. *Elife* 2021;10. doi: 10.7554/eLife.60999
- 526 50. Wirleitner B, Rudzite V, Neurauter G, et al. Immune activation and degradation of
- tryptophan in coronary heart disease. *European journal of clinical investigation* 2003;**33**:550554. doi:
- 529 51. Mangge H, Stelzer I, Reininghaus E, *et al.* Disturbed tryptophan metabolism in 530 cardiovascular disease. *Current medicinal chemistry* 2014;**21**:1931-1937. doi:
- 531 52. Liu G, Chen S, Zhong J, Teng K, Yin Y. Crosstalk between tryptophan metabolism and
- cardiovascular disease, mechanisms, and therapeutic implications. *Oxidative Medicine and Cellular Longevity* 2017;2017. doi:
- 53. Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev
- 535 *Microbiol* 2021;**19**:55-71. doi: 10.1038/s41579-020-0433-9
- 536 54. Agus A, Clément K, Sokol H. Gut microbiota-derived metabolites as central regulators in
- 537 metabolic disorders. *Gut* 2021;**70**:1174-1182. doi: 10.1136/gutjnl-2020-323071
- 538 55. Dietrich M, Traber MG, Jacques PF, *et al.* Does γ-tocopherol play a role in the primary
- prevention of heart disease and cancer? A review. *Journal of the American College of Nutrition*
- 540 2006;**25**:292-299. doi:
- 541 56. Mathur P, Ding Z, Saldeen T, Mehta JL. Tocopherols in the prevention and treatment of
- 542 atherosclerosis and related cardiovascular disease. *Clinical cardiology* 2015;**38**:570-576. doi:
- 543 57. Würtz P, Wang Q, Kangas AJ, et al. Metabolic signatures of adiposity in young adults:

- 544 Mendelian randomization analysis and effects of weight change. *PLoS Med* 2014;**11**:e1001765.
- 545 doi: 10.1371/journal.pmed.1001765
- 546 58. Lauterbach MA, Latz E, Christ A. Metabolomic Profiling Reveals Distinct and Mutual
- 547 Effects of Diet and Inflammation in Shaping Systemic Metabolism in Ldlr(-/-) Mice.
- 548 *Metabolites* 2020;**10**. doi: 10.3390/metabo10090336
- 549 59. Sato S, Dyar KA, Treebak JT, et al. Atlas of exercise metabolism reveals time-dependent
- signatures of metabolic homeostasis. *Cell Metabolism* 2022;**34**:329-345. e328. doi:
- 551 60. Cruickshank-Quinn CI, Mahaffey S, Justice MJ, et al. Transient and persistent
- 552 metabolomic changes in plasma following chronic cigarette smoke exposure in a mouse model.
- 553 *PloS one* 2014;**9**:e101855. doi:

29

555 Figure legends

556 Fig. 1. Overview of the current study. This study involved two nested case-control

metabolomics studies within Southern Community Cohort Study (SCCS, primary cohort) and 557 Shanghai Women's and Men's Health Studies (SWMHS, validation cohort). In the follow-up 558 visits, participants with incident coronary heart disease (CHD) were identified and matched 559 with controls by enrollment age, sex, race, fasting time, and time between sample collection 560 and lab processing. After excluding 8 samples that did not pass metabolomics quality control, 561 1194 SCCS participants and 598 SWMHS participants were included. Metabolite signature of 562 563 Life's Essential 8 (LE8) were identified using elastic net regression with leave-one-out crossvalidation in SCCS. The associations of LE8 score and its metabolite signature with risk of 564 CHD were evaluated by conditional logistic regression adjusted for confounders. Mediation 565 566 analysis was performed to assess the potential mediating role of metabolite signature on the LE8-CHD association. External validity of the identified metabolite signature related to LE8 567 score and CHD risk was investigated in SWMHS. 568 569 Abbreviations: SCCS, Southern Community Cohort Study; SWMHS, Shanghai Women's and Men's Health Studies; CHD, coronary heart disease; LE8, Life's Essential 8; MetaSig, 570 metabolite signature. 571

572

Fig. 2. The metabolite signature of LE8 and its association with risk of CHD. (A) Top 30
metabolites selected by elastic net regression in SCCS. Metabolites were ranked by the
absolute value of regression coefficients. (B) *Spearman* correlation between MetaSig and
LE8 score in SCCS. The dashed line denotes median LE8 score. (C) *Spearman* correlation

30

577	between MetaSig and LE8 score in SWMHS. (D) The mediation effect of MetaSig on the
578	association between LE8 score and risk of CHD in SCCS. (E) The mediation effect of
579	MetaSig on the association between LE8 score and risk of CHD in SWMHS.
580	Abbreviations: SCCS, Southern Community Cohort Study; SWMHS, Shanghai Women's
581	and Men's Health Studies; LE8, Life's Essential 8; MetaSig, metabolite signature; ACME,
582	average causal mediation effects; ADE, average direct effects; CHD, coronary heart disease.
583	
584	Fig. 3. Subgroup analyses for the associations of LE8 score and its metabolite signature
584 585	Fig. 3. Subgroup analyses for the associations of LE8 score and its metabolite signature with risk of CHD in SCCS. (A) Subgroup analysis for the association between LE8 score
584 585 586	Fig. 3. Subgroup analyses for the associations of LE8 score and its metabolite signature with risk of CHD in SCCS. (A) Subgroup analysis for the association between LE8 score and risk of CHD. (B) Subgroup analysis for the association between MetaSig and risk of
584 585 586 587	Fig. 3. Subgroup analyses for the associations of LE8 score and its metabolite signature with risk of CHD in SCCS. (A) Subgroup analysis for the association between LE8 score and risk of CHD. (B) Subgroup analysis for the association between MetaSig and risk of CHD. Conditional logistic regression models were used, adjusted for potential confounders.
584 585 586 587 588	Fig. 3. Subgroup analyses for the associations of LE8 score and its metabolite signature with risk of CHD in SCCS. (A) Subgroup analysis for the association between LE8 score and risk of CHD. (B) Subgroup analysis for the association between MetaSig and risk of CHD. Conditional logistic regression models were used, adjusted for potential confounders. For income, lower income denotes low income and higher income denotes middle and high
584 585 586 587 588 589	Fig. 3. Subgroup analyses for the associations of LE8 score and its metabolite signature with risk of CHD in SCCS. (A) Subgroup analysis for the association between LE8 score and risk of CHD. (B) Subgroup analysis for the association between MetaSig and risk of CHD. Conditional logistic regression models were used, adjusted for potential confounders. For income, lower income denotes low income and higher income denotes middle and high income.

591 CHD, coronary heart disease; LE8, Life's Essential 8; OR, odds ratio; CI, confidence interval.

	Black partic	ipants (<i>N</i> =598)	White partic	pipants (N=596)	
	CHD (<i>N</i> =299)	Control (N=299)	CHD (<i>N</i> =298)	Control (N=298)	
Age, years	54.9 (8.8)	54.7 (8.7)	55.2 (8.7)	55.1 (8.6)	
Male, <i>n</i> (%)	149 (49.8)	149 (49.8)	148 (49.7)	148 (49.7)	
Education, <i>n</i> (%)					
Less than high school	120 (40.1)	109 (36.5)	108 (36.2)	84 (28.2)	
Completed high school	107 (35.8)	108 (36.1)	118 (39.6)	118 (39.6)	
Vocational school or some	57 (10.1)	(0, (20, 1))	52 (17.4)	54 (19.1)	
college	57 (19.1)	60 (20.1)	52 (17.4)	54 (18.1)	
College or graduate school	15 (5.0)	22 (7.4)	20 (6.7)	42 (14.1)	
Income, <i>n</i> (%)*					
Low	194 (64.9)	185 (61.9)	196 (65.8)	167 (56.0)	
Middle	100 (33.4)	104 (34.8)	92 (30.9)	111 (37.2)	
High	5 (1.7)	10 (3.3)	10 (3.4)	20 (6.7)	
Alcohol intake, n (%)**					
None	154 (51.5)	140 (46.8)	175 (58.7)	140 (47.0)	
Moderate	94 (31.4)	107 (35.8)	98 (32.9)	129 (43.3)	
Heavy	51 (17.1)	52 (17.4)	25 (8.4)	29 (9.7)	
Family history of CHD, n (%)	107 (35.8)	89 (29.8)	168 (56.4)	142 (47.7)	
History of diabetes, n (%)	116 (38.8)	56 (18.7)	96 (32.2)	40 (13.4)	
History of dyslipidemia, n (%)	102 (34.1)	91 (30.4)	155 (52.0)	108 (36.2)	
History of hypertension, n (%)	210 (70.2)	179 (59.9)	177 (59.4)	133 (44.6)	
LE8 score	45.9 (11.9)	52.2 (13.2)	45.0 (13.5)	51.5 (13.5)	
LE8 score category, n (%)***					
High (80-100)	0 (0)	7 (2.3)	3 (1.0)	10 (3.4)	
Moderate (50-79)	114 (38.1)	174 (58.2)	100 (33.6)	148 (49.7)	
Low (0-49)	185 (61.9)	118 (39.5)	195 (65.4)	140 (47.0)	
Health behaviors score	43.8 (18.4)	47.4 (20.5)	42.0 (19.2)	46.3 (21.0)	
Health factors score	47.2 (20.4)	56.7 (21.3)	48.0 (20.7)	56.2 (20.1)	
Diet score	39.8 (32.2)	41.6 (30.6)	36.9 (30.3)	40.8 (32.3)	
Physical activity score	22.8 (39.8)	24.2 (40.5)	19.9 (38.8)	21.3 (39.1)	
Smoking score	43.0 (42.2)	47.8 (42.5)	40.0 (40.3)	46.5 (42.0)	
Sleep score	72.3 (29.2)	77.1 (26.6)	71.2 (29.7)	78.1 (26.6)	
BMI score	50.0 (34.5)	56.9 (35.3)	50.4 (34.1)	57.7 (34.2)	
Blood lipids score	36.8 (32.8)	44.6 (31.8)	25.8 (28.7)	27.9 (27.6)	
Blood glucose score	54.3 (34.3)	69.6 (30.0)	60.9 (34.0)	73.3 (26.7)	
Blood pressure score	47.7 (35.1)	55.8 (37.3)	54.9 (38.3)	65.9 (38.9)	

592 Table 1. Characteristics of study participants in the Southern Community Cohort Study

593 Data were mean (standard deviation) or *n* (%) as indicated.

*Annual household income <\$15,000, \$15,000 to <\$25,000, and ≥\$25,000 for low, middle, and high levels of
income, respectively.

596 **Alcohol intake was grouped as none, moderate (>0 to ≤ 2 drinks per day in men or >0 to ≤ 1 drink per day in

597 women; 1 drink = 14 g ethanol), and heavy drinking (>2 drinks per day in men or >1 drink per day in women).

^{***}The cutoffs were provided by the American Heart Association (Lloyd-Jones *et al.*, 2022).

599 Abbreviations: CHD, coronary heart disease; LE8, Life's Essential 8; BMI, body mass index.

33

		OR (95% CI)	Р
	SCCS		
LE8	LE8 score	0.61 (0.53-0.69)	< 0.001
	MetaSig	0.57 (0.49-0.65)	< 0.001
	MetaSig (adjusting for LE8 score)	0.66 (0.55-0.78)	< 0.001
Health behaviors	Health behaviors score	0.77 (0.67-0.88)	< 0.001
	MetaSig	0.73 (0.63-0.85)	< 0.001
	MetaSig (adjusting for health behaviors score)	0.79 (0.67-0.94)	0.007
Health factors	Health factors score	0.61 (0.53-0.7)	< 0.001
	MetaSig	0.57 (0.49-0.66)	< 0.001
	MetaSig (adjusting for health factors score)	0.68 (0.55-0.84)	< 0.001
	SWMHS		
LE8	LE8 score	0.52 (0.42-0.65)	< 0.001
	MetaSig	0.57 (0.46-0.69)	< 0.001
	MetaSig (adjusting for LE8 score)	0.69 (0.55-0.86)	< 0.001
Health behaviors	Health behaviors score	0.73 (0.59-0.9)	0.003
	MetaSig	0.69 (0.55-0.87)	0.001
	MetaSig (adjusting for health behaviors score)	0.77 (0.59-0.99)	0.043
Health factors	Health factors score	0.5 (0.4-0.62)	< 0.001
	MetaSig	0.57 (0.47-0.7)	< 0.001
	MetaSig (adjusting for health factors score)	0.80 (0.62-1.04)	0.093

Table 2. The associations of LE8 score, health behaviors score, health factors score and their related metabolite signatures with risk of CHD*

602 * For associations of LE8 score and its related metabolite signature with risk of CHD, we used the conditional 603 logistic regression, adjusted for age, education, income, alcohol intake, family history of CHD. For 604 associations of health behaviors score and health factors score and their related metabolite signatures with 605 risk of CHD, we used the conditional logistic regression, adjusted for age, education, income, alcohol intake, 606 family history of CHD, and mutual adjustments of health factors score/health behaviors score.

Abbreviations: SCCS, Southern Community Cohort Study; SWMHS, Shanghai Women's and Men's Health
 Studies; CHD, coronary heart disease; LE8, Life's Essential 8; MetaSig, metabolite signature; OR, odds ratio; CI,

609 confidence interval.

34

611 Fig. 1. Overview of the current study



A в Top 30 metabolites in MetaSig SCCS cotinine 80 cholesterol hydrochlorothiazide 5-(galactosylhydroxy)-L-lysine 60 metformin MetaSig sphingomyelin (d18:2/16:0, d18:1/16:1)* 4-hydroxy-2-oxoglutaric acid 40 X-11315 fructosyllysine 20 r = 0.61, p < 0.001sphingomyelin (d18:0/18:0, d19:0/17:0)* 1-palmitoleoylglycerol (16:1)* mannose delta-CEHC glucuronide 60 80 100 gamma-tocopherol/beta-tocopherol LE8 score X-23654 С methylnaphthyl sulfate (2)* SWMHS gamma-glutamylisoleucine* 2-ethylphenylsulfate 80 X-25433 alpha-tocopherol 60 maltotetraose MetaSig X-12100 ethyl beta-glucopyranoside tartronate (hydroxymalonate) X-21310 X-12851 20 r = 0.49, P < 0.001 X-24334 octadecadienedioate (C18:2-DC)* 0 (2,4 or 2,5)-dimethylphenol sulfate 100 20 60 80 0 4-imidazoleacetate LE8 score -2 0 Beta coefficients D Е SCCS SWMHS MetaSig MetaSig 190 St. 01, (\$9.0'95:0) 9.0 90 53.0% 27.4% _{medi} < 0.001 medi < 0.001 ADE=-0.06, P=0.004 ADE=-0.11, P < 0.001 CHD CHD LE8 score LE8 score 615

614 Fig. 2. The metabolite signature of LE8 and its association with risk of CHD



36

Fig. 3. Subgroup analyses for the associations of LE8 score and its metabolite signature with risk of CHD in SCCS

A	LE8 sco	re-CHI	D associations		
Variable	Subgroup		OR (95% CI)	P value	P for interaction
Race	White	H	0.64 (0.53-0.78)	< 0.001	0.26
	Black	H	0.57 (0.46-0.69)	< 0.001	
Age	>= 60	Hert	0.62 (0.47-0.82)	0.001	0.669
	< 60	H	0.6 (0.51-0.71)	< 0.001	
Sex	Female	H	0.53 (0.42-0.66)	< 0.001	0.017
	Male	-	0.66 (0.55-0.8)	< 0.001	
Education	> High school)	0.5 (0.25-1)	0.05	0.334
	<= High school	H	0.56 (0.47-0.68)	< 0.001	
Income	Higher	H=H	0.56 (0.38-0.82)	0.003	0.872
	Lower	Heit	0.72 (0.59-0.88)	0.002	
Diabetes	Yes		0.84 (0.42-1.66)	0.612	0.718
	No	I=I	0.69 (0.58-0.82)	< 0.001	
Hypertensio	on Yes	le l	0.76 (0.61-0.95)	0.014	0.156
	No	H=H	0.5 (0.35-0.71)	< 0.001	
Dyslipidem	ia Yes	Hert	0.67 (0.48-0.95)	0.024	0.863
	No	(Hell	0.63 (0.51-0.79)	< 0.001	
		0.2 1	18		
		Oddds r	atio		

В

LE8 MetaSig-CHD associations

Variable	Subgroup		OR (95% CI)	P value	P for interaction
Race	White	I=I	0.63 (0.52-0.78)	< 0.001	0.087
	Black	-	0.5 (0.41-0.62)	< 0.001	
Age	>= 60	Hert	0.69 (0.53-0.89)	0.005	0.078
	< 60		0.54 (0.45-0.64)	< 0.001	
Sex	Female	H	0.48 (0.38-0.6)	< 0.001	0.016
	Male	1-12	0.65 (0.54-0.78)	< 0.001	
Education	> High school	+•1	0.42 (0.21-0.85)	0.015	0.59
	<= High school	 ••	0.57 (0.47-0.69)	< 0.001	
Income	Higher	H	0.56 (0.38-0.83)	0.003	0.972
	Lower	H=1	0.61 (0.49-0.77)	< 0.001	
Diabetes	Yes	+	0.47 (0.23-0.94)	0.033	0.711
	No	-	0.66 (0.56-0.79)	< 0.001	
Hypertension	Yes	I=I	0.65 (0.52-0.81)	< 0.001	0.179
	No	Hert	0.43 (0.29-0.63)	< 0.001	
Dyslipidemia	Yes		0.69 (0.49-0.97)	0.034	0.309
	No	I=I	0.61 (0.49-0.76)	< 0.001	
		0.2 1 Oddds	1.8 ratio		